In the article by Witteles and Bosch, “Myocardial Protection During Cardiotoxic Chemotherapy”, which published in the November 10, 2015 issue of the journal (Circulation. 2015;132:1835–1845. DOI: 10.1161/CIRCULATIONAHA.115.010486), several corrections are needed:
On p 1838, the reference at the end of the first paragraph under the subheading “Trastuzumab” should be 9, not 35.
On p 1838, the second line under the subheading “Tyrosine Kinase Inhibitors” should read TKIs instead of TKI.
On p 1838, the last sentence in the second paragraph under the subheading “Biomarkers” should read: “Troponin rises almost always occurred prior to trastuzumab invitation or very early during trastuzumab therapy, supportive of the theory that troponin rises mainly reflected anthracycline effects rather than direct effects from the trastuzumab itself. Nevertheless, troponin elevations remained predictive of outcomes in their cohort, with patients with positive troponin having a 62% incidence of a significant LVEF drop compared with 5% in patients with negative troponins.42”
On p 1839, the end of the first sentence under the subheading “Primary Prevention Measures” should read “Stage A HF” rather than “Stage A.”
On p 1842, in Figure 3, the third box from the left should read “Begin CT (Stage A)”.
On p 1842, in the third line of the second paragraph under the subheading “Future Directions”, “LVEF drop” should read “LVEF drops”.
On p 1842, in the second line of the third paragraph under the subheading “Future Directions”, the correct references are 21,22 rather than 8,9.
The correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/content/132/19/1835.full.
- © 2016 American Heart Association, Inc.